Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients
Details
Serval ID
serval:BIB_0B94F1482735
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients
Journal
AIDS
ISSN
0269-9370 (Print)
ISSN-L
0269-9370
Publication state
Published
Issued date
2007
Volume
21
Number
9
Pages
1210-3
Language
english
Notes
Delaugerre, Constance
Mathez, Dominique
Peytavin, Gilles
Berthe, Huguette
Long, Kivan
Galperine, Tatiana
de Truchis, Pierre
eng
England
2007/05/16
AIDS. 2007 May 31;21(9):1210-3. doi: 10.1097/QAD.0b013e32810fd744.
Mathez, Dominique
Peytavin, Gilles
Berthe, Huguette
Long, Kivan
Galperine, Tatiana
de Truchis, Pierre
eng
England
2007/05/16
AIDS. 2007 May 31;21(9):1210-3. doi: 10.1097/QAD.0b013e32810fd744.
Abstract
In highly experienced HIV-1-infected patients, a ritonavir-boosted darunavir-containing regimen was associated with dramatic immunological and virological efficacy. Patients harbouring viruses with amprenavir-specific resistance profiles, such as I50V or V32I + I47V, failed on a darunavir/ritonavir-containing regimen. These key amprenavir mutations were also selected at the time of failure, suggesting their impact on darunavir efficacy.
Keywords
CD4 Lymphocyte Count, Carbamates/*therapeutic use, Darunavir, Drug Resistance, Viral/genetics, Drug Therapy, Combination, Furans, HIV Infections/*drug therapy/genetics/virology, HIV Protease Inhibitors/*therapeutic use, HIV-1/*genetics, Humans, Reverse Transcriptase Inhibitors/therapeutic use, Risk Factors, Ritonavir/therapeutic use, Sulfonamides/*therapeutic use, Treatment Failure, Viral Load
Pubmed
Create date
30/01/2023 12:16
Last modification date
31/01/2023 7:55
Usage data
